Qualified Health vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Enterprise AI for health systems; raised $125M Series B (NEA + Anthropic fund, March 2026); 500K+ users; AI agents covering ~7% of US hospital revenue; integrates with existing EHR systems
About
Qualified Health is an enterprise AI company building intelligent systems for large health systems and hospital networks. Founded to address the complexity of clinical and operational decision-making in healthcare, the company develops AI agents that assist clinicians, administrators, and care teams with data-intensive workflows. Its platform is designed to integrate with existing electronic health record systems and enterprise infrastructure, enabling health systems to deploy AI without replacing legacy technology.\n\nThe company targets enterprise health systems — specifically the largest hospital networks in the United States — with AI tools that span clinical decision support, administrative automation, and patient engagement. Qualified Health emphasizes safety, compliance, and interpretability in its models, which is critical for adoption in regulated healthcare settings. The platform is built to handle the scale and data sensitivity requirements of organizations managing hundreds of thousands of patients.\n\nQualified Health raised a $125M Series B led by NEA and backed by the Anthropic fund, signaling strong confidence from both traditional healthcare investors and AI-native institutional backers. The company has grown to 500,000+ users and its platform now touches approximately 7% of total US hospital revenue — a remarkable reach for a relatively young company. As of early 2026, Qualified Health is one of the best-capitalized enterprise health AI startups in the market.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.